WEBULL

Viridian Therapeutics (VRDN) Is Up 15.9% After Securing $300M Royalty Financing for Eye Disease Pipeline

Simply Wall St · 10/21/2025 12:22
  • DRI Healthcare Trust recently announced a royalty financing agreement with Viridian Therapeutics, potentially providing up to US$300 million to help advance the commercial launch of veligrotug and VRDN-003 for thyroid eye disease.
  • The deal structure, which includes tiered royalties and milestone payments linked to clinical and regulatory progress, signals confidence in the future impact of Viridian’s thyroid eye disease pipeline.
  • We’ll explore how the non-dilutive capital from this royalty deal could reshape Viridian’s investment narrative as veligrotug nears regulatory submission.

We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

What Is Viridian Therapeutics' Investment Narrative?

To be a shareholder in Viridian Therapeutics right now, you’d need conviction in both the addressable market for thyroid eye disease and the company’s ability to convert promising late-stage data into regulatory approvals and future sales. The new $300 million royalty financing agreement with DRI Healthcare Trust delivers a significant injection of non-dilutive capital, potentially shifting some of the biggest near-term risks. Before this, capital constraints and the risk of further equity dilution were front and center, given steep and rising net losses paired with minimal revenue. This funding could meaningfully extend Viridian’s runway, fast-track its BLA submission for veligrotug, and support major clinical milestones for both veligrotug and VRDN-003. Short-term catalysts now focus even more squarely on upcoming clinical readouts and regulatory decisions, while risks shift towards clinical trial outcomes, regulatory approval, and long-term commercial execution. However, the underlying challenge remains: Viridian is still a pre-revenue biotech heavily dependent on successful trial results and competitive positioning. Yet, there are crucial risks around trial outcomes that every investor should keep in mind.

Viridian Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

VRDN Community Fair Values as at Oct 2025
VRDN Community Fair Values as at Oct 2025
The Simply Wall St Community offers three unique fair value estimates for Viridian, ranging from as low as US$0.18 to almost US$388 per share. While some see extreme upside, others remain far more cautious. Against this backdrop of wide opinion, short-term fate still hinges on critical trial results and regulatory milestones.

Explore 3 other fair value estimates on Viridian Therapeutics - why the stock might be worth less than half the current price!

Build Your Own Viridian Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.